Gerianne realized the women's healthcare market was under-penetrated because current treatment options were unacceptable to women. Women's diseases are often unique because women must use drugs chronically. In addition, women's diseases affecting the reproductive system, while not life threatening, can impact enormously on their quality of life. Many currently available therapeutic modalities place women in a quandary - to live with the disease or take therapeutic regimens that carry significant side effects. 

By providing safe, effective drugs that do not have the systemic side effects which result in discontinuation of treatment, FemmePharma Global Healthcare, Inc. aims to tap the formidable market that is women's healthcare and, at the same time, offer much needed choices to those affected with these terrible women's diseases and disorders.

Executive Team

Gerianne Tringali DiPiano
President and CEO
Company Founder

• Worked extensively in the women's health area, in sales, marketing, medical affairs, and new product development and business development.
• An inventor of the patented technologies that are assigned to FemmePharma Global Healthcare, Inc..
• Has over two decades of experience in the pharmaceutical industry.
• Former President and Chief Operating Officer of a diagnostic clinical laboratory.
• Has held academic appointments as Adjunct Professor of Marketing and Director of the MBA program at St. Joseph's University in Philadelphia, PA.
• Currently serves on the Board of Trustees for Drexel University, Philadelphia, PA and the Corporate Advisory Board of the Society for Gynecologic Investigation.

Peter K. Mays, Ph.D.
Pharmaceutical Development

• Strong background in start-up and early stage pharmaceutical companies.
• Former Vice President - Pharmaceutical Development for CheckPoint Genetics, Inc.
• As Director of Research and Development for Collagenesis was responsible for overall project management, including timeline, budget, resource allocation and design control.
• Extensive experience filing INDs, PMAs, NDAs.

Joseph A. Plevelich
Commercial Operations

• Comprehensive senior management, P & L, sales/marketing and business development experience.
• Has built successful sales teams, corporate partnerships and distributor licensee operations worldwide.
• As Vice President-Worldwide Sales and Marketing for INO Therapeutics, directed the development and implementation of worldwide sales and marketing activities for INOtherapy, the first selective pulmonary vasodilator.
• Past experience includes Worldwide Director - Glucose Monitoring Systems, Becton Dickinson and Assistant Vice President New Products Marketing/Business Development, Wyeth Ayerst International.

Kim Groff
Corporate Communications/Investor Relations

• Over 10 years of experience in strategic marketing for start-up and turn-around organizations.
• Extensive experience in fund raising for early, mid and late stage companies.
• Former owner of CareerMatch, a human resource consulting organization.

Jessica A. Donahue, BS, MPH
Clinical Operations

• Experience in all aspects of monitoring, site and project management from start-up through close-out.
• Substantial clinical trial experience in Phases IIa through IV.
• Most recently worked as an Independent Clinical Research Consultant; prior experience includes performing as Project Manager for Quintiles, Inc.

Scientific Advisory Board

Jerome Strauss, MD, Ph.D. 
Department of Reproductive Biology 
University of Pennsylvania

W. Paul Dmowski MD, Ph.D. 
Director Institute for the Study and Treatment of Endometriosis
www.oakbrookfertility.com

Sheldon Segal, Ph.D. 
Distinguished Scientist
The Population Council
www.populationcouncil.com

Thomas I. Janicki, MD
University Suburban Health Center
www.EndometriosisUSA.com